(NP (NP (NN Influence)) (PP (IN of) (NP-COOD (NP (NN estradiol)) (CC and) (NP (NN tamoxifen)))) (PP (IN on) (NP (NP (NN susceptibility)) (PP (IN of) (NP (JJ human) (NN breast) (NN cancer) (NN cell) (NNS lines))) (PP (TO to) (NP (NP (NN lysis)) (PP (IN by) (NP (JJ lymphokine-activated) (NN killer) (NNS cells))))))) (. .))
(S (NP-SBJ-58 (NP (DT The) (NN design)) (PP (IN of) (NP (NP (NN combination) (ADJP-COOD (ADJP (JJ hormonal)) (CC and) (ADJP (JJ immunotherapeutic))) (NNS protocols)) (PP (IN for) (NP (NN breast) (NN cancer) (NNS patients)))))) (VP (MD may) (VP (VB be) (VP (VBN facilitated) (NP (-NONE- *-58)) (PP (IN by) (NP-LGS (NP (NN analysis)) (PP (IN of) (NP (JJ preclinical) (ADJP (FW in) (FW vitro)) (JJ model) (NNS systems)))))))) (. .))
(S (NP-SBJ-200 (NN Estrogen) (NN receptor) (ADJP-COOD (ADJP (ADJP (JJ positive)) (PRN (-LRB- -LRB-) (FRAG (ADJP (JJ ER+)) (: :) (NP (NN MCF-7))) (-RRB- -RRB-))) (CC and) (ADJP (ADJP (JJ negative)) (PRN (-LRB- -LRB-) (FRAG (ADJP (JJ ER-)) (: :) (NP (NN MDA-MB-231))) (-RRB- -RRB-)))) (JJ human) (NN breast) (NN cancer) (NN cell) (NNS lines)) (VP (VBD were) (VP (VBN utilized) (NP (-NONE- *-200)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP-COOD (NP (NP (NN tamoxifen)) (PRN (-LRB- -LRB-) (NP (NN TAM)) (-RRB- -RRB-))) (CC and) (NP (NP (NN estradiol)) (PRN (-LRB- -LRB-) (NP (NN E2)) (-RRB- -RRB-))))) (PP (IN on) (NP (NP (NN modulation)) (PP (IN of) (NP (NP (NN breast) (NN cancer) (NN target) (NN susceptibility)) (PP (TO to) (NP (NP (NN lysis)) (PP (IN by) (NP (NP (NP (JJ lymphokine-activated) (NN killer)) (PRN (-LRB- -LRB-) (NP (NN LAK)) (-RRB- -RRB-))) (NNS cells))))))))))))))) (. .))
(S (NP-SBJ (JJ E2-stimulated) (JJ ER+) (NNS cells)) (VP (VBD were) (ADJP-PRD (ADJP (RBR more) (JJ susceptible) (PP (TO to) (NP (NP (NN lysis)) (PP (IN by) (NP (NN LAK) (NNS cells)))))) (PP (IN than) (NP (VBG corresponding) (UCP-COOD (ADJP (JJ TAM-treated)) (CC or) (NP (NN control))) (NNS cells)))) (, ,) (SBAR (IN while) (S (NP-SBJ (NP (NN treatment)) (PP (IN of) (NP (JJ ER-) (NNS cells))) (PP (IN with) (NP (NP-COOD (CC either) (NP (NN E2)) (CC or) (NP (NN TAM))) (ADVP (RB alone))))) (VP (VBD did) (RB not) (VP (VB alter) (PP (IN from) (NP (NN control))) (NP (NP (PRP$ their) (NN susceptibility)) (PP (TO to) (NP (DT this) (JJ immune-mediated) (NN lysis))))))))) (. .))
(S (NP-SBJ (NP (DT All) (ADJP-COOD (ADJP (JJ ER+)) (CC and) (ADJP (JJ ER-))) (NNS cells)) (VP (VBN tested) (NP (-NONE- *)))) (VP (VBD remained) (ADJP-PRD (JJ sensitive) (PP (-NONE- *ICH*-201))) (PP-TMP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NN TAM))))) (PP-201 (TO to) (NP (NP (NN lysis)) (PP (IN by) (NP (NN LAK) (NNS cells)))))) (. .))
(S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-59 (NP (DT an) (ADJP (NP (NN adenocarcinoma)) (JJ reactive)) (ADJP (JJ human-mouse) (JJ chimeric)) (JJ monoclonal) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NN ING-1)) (-RRB- -RRB-))) (VP (VBD was) (ADJP-PRD (JJ able) (S (NP-SBJ (-NONE- *-59)) (VP (TO to) (ADVP (RB significantly)) (VP (VB boost) (NP (NP (ADJP (ADVP (FW in) (FW vivo)) (VBN generated)) (ADJP (NN LAK) (JJ cell-mediated)) (NN lysis)) (PP (IN of) (NP (UCP-COOD (NP (NN control)) (, ,) (ADJP (JJ E2-treated)) (, ,) (CC and) (ADJP (JJ TAM-treated))) (ADJP-COOD (ADJP (JJ ER+)) (CC and) (ADJP (JJ ER-))) (NNS cells))))))))) (. .))
(S (NP-SBJ (DT These) (ADJP (FW in) (FW vitro)) (NNS results)) (VP (VBP provide) (NP (NP (DT a) (JJ preclinical) (NN rationale)) (PP (IN for) (NP (NP (ADJP (FW in) (FW vivo)) (NN testing)) (PP (IN of) (NP (NP-COOD (NP (NN TAM)) (, ,) (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN breast) (NN cancer) (JJ reactive) (JJ antibody-dependent) (JJ cellular) (NN cytotoxicity))) (VP (VBG facilitating) (NP (NN antibody)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (UCP-COOD (ADJP (JJ refractory)) (CC or) (NP (JJ high) (NN risk))) (NN breast) (NN cancer)))))))))))) (. .))
